Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Mesoblast Limited ( (AU:MSB) ) is now available.
JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders of Mesoblast Limited, as indicated in the recent notice. This change in holdings could impact Mesoblast’s market dynamics and investor perceptions, as JPMorgan’s involvement often signals confidence in a company’s potential.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited operates in the biotechnology industry, focusing on the development and commercialization of innovative cellular medicines. The company primarily targets the treatment of inflammatory diseases, cardiovascular conditions, and back pain, leveraging its proprietary mesenchymal lineage cell technology.
Average Trading Volume: 5,659,932
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$3.06B
For a thorough assessment of MSB stock, go to TipRanks’ Stock Analysis page.